Autologous insulin developer Orgenesis forms Israeli cell therapy JV

By Dan Stanton contact

- Last updated on GMT

Image: iStock/CountDuckula
Image: iStock/CountDuckula

Related tags: Cell therapy, Stem cell

Orgenesis and Atvio have formed a cell therapy contract manufacturing joint venture and are looking to procure a GMP facility in Israel.

Orgenesis is a Maryland-based biotech which is using its Autologous Insulin Producing (AIP) cell transplantation technology to develop a cell therapy for diabetes.

According to an SEC filing​, the firm has entered into a 50-50 joint venture with newly formed Israeli company Atvio Biotech in order to form a contract development and manufacturing organisation (CDMO) for cell and virus therapy products in the field of regenerative medicine within Israel.

While Orgenesis did not respond to for more information, the filing says the firm has paid Atvio has been charged with setting up and maintaining a GMP facility in Israel, and has received $1m from Orgenesis to cover the costs.

“[Orgenesis] will share with Atvio the Company’s know-how in the field of cell therapy manufacturing, which know-how will not include the intellectual property included in the license from the Tel Hashomer Hospital in Israel to Orgenesis Ltd., the Company’s subsidiary,”​ the filing added.

The company’s initial product takes a liver biopsy from the patient, sends it to a central laboratory where the manufacturing platform is used to produce a sufficient amount of AIP cells which are then transplanted back into a patient’s liver.

In March 2015​, the firm acquired contract manufacturer Masthercell SA to help progress the treatment into the clinic, adding a GMP production facility in Gosselies, Belgium.

If proven clinically successful, the firm claims the regeneration of functional insulin-producing cells could transform the diabetes treatment space.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us


View more